---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-22-000041"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:49:56.052862+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q2 revenue record $5.2M (+52% YoY); reaffirms 2022 guidance

## Summary
- Quarterly revenue $5.2M (record), up 52% YoY; biologics/drug delivery revenue $2.4M +73%.
- Partner PTC Therapeutics received EU marketing authorization for Upstaza; uses ClearPoint SmartFlow Neuro Cannula.
- Reaffirmed FY2022 revenue guidance of $21-22M.
- Cash and short-term investments $45.1M at June 30, 2022.
- Added >45 partners; installed 8 systems YTD (4 in Q2).

## SEC filing metadata
- accession: 0001285550-22-000041
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555022000041/0001285550-22-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555022000041/clpt-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-22-000041
- JSON: https://secwatch.observer/filing/0001285550-22-000041.json
- Plain text: https://secwatch.observer/filing/0001285550-22-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.